Onco-hematology
RCT | Overall survival with Daratumumab, Lenalidomide, and Dexamethasone in previously treated multiple myeloma
16 Mar, 2023 | 13:07h | UTCOriginal Study: Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma – New England Journal of Medicine
Primary myelofibrosis | 2023 update on diagnosis, risk-stratification, and management
16 Mar, 2023 | 12:57h | UTC
Retrospective Cohort | Arrhythmogenic cardiotoxicity associated with contemporary treatments of lymphoproliferative disorders
14 Mar, 2023 | 13:27h | UTC
DNA sequencing may identify an increased risk of relapse in adults with AML prior to hematopoietic cell transplantation
13 Mar, 2023 | 14:47h | UTCDNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell Transplant – JAMA (free for a limited period)
Commentary on Twitter
Among patients w AML in first remission prior to allogeneic hematopoietic cell transplant, the persistence of residual variants in the blood at an allele fraction ≥0.01% was assoc'd w increased relapse & worse survival vs those w/o these variants. https://t.co/KCnaQ1NRXJ
— JAMA (@JAMA_current) March 11, 2023
Cohort Study | Personalized progression prediction in patients with MGUS or smouldering multiple myeloma
9 Mar, 2023 | 13:59h | UTCInvited Commentary: The PANGEA model: catching the drift from precursor conditions to myeloma in individual patients – The Lancet Haematology
Commentary from the author on Twitter (thread – click for more)
‼️ The PANGEA Model is out now @TheLancetHaem ‼️
A 🧵on how PANGEA improves prediction accuracy of MGUS & SMM progression to #MultipleMyeloma & is the 1st model that is #personalized to the individual #mmsm patient! @LabGhobrial @DanaFarber | 1/https://t.co/e2rEWXLahT
— Annie (@anniencowan) February 28, 2023
RCT | Momelotinib vs. danazol in symptomatic patients with anemia and myelofibrosis
1 Mar, 2023 | 13:39h | UTCMomelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study – The Lancet (link to abstract – $ for full-text)
Cohort Study | Risk of second primary malignancies in patients with chronic lymphocytic leukemia
28 Feb, 2023 | 13:27h | UTC
Commentary on Twitter
Our recent population-based study shows that patients with chronic lymphocytic leukemia (CLL) have an increased risk of developing second primary malignancies (SPMs) in the long term. 1/3#CLLsm #OpenAccess #NKRdata #IKNL @BloodCancerJnl @IKNL https://t.co/epgVnnwv2W
— Dr. Avinash Dinmohamed (@ADinmohamed) January 19, 2023
RCT | Ide-cel (a CAR-T cell treatment) vs. standard regimens in relapsed and refractory multiple myeloma
13 Feb, 2023 | 12:41h | UTCIde-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Ide-Cel Beneficial in Relapsed, Refractory Multiple Myeloma – HealthDay
Ide-cel Improves PFS vs SOC in Relapsed/Refractory Multiple Myeloma – OncLive
RCT | Allo-HCT vs. standard consolidation chemotherapy in patients with intermediate-risk AML
13 Feb, 2023 | 12:40h | UTCAllogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia: A Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary on Twitter
Rand trial suggests pts with intermediate-risk AML & matched donor have a significantly improved disease free-survival with allo-HCT during first complete remission (69% vs. 40%) but similar overall surv w/consol chemo & allo HCT only after relapse. https://t.co/TJR9fqcYc9
— JAMA Oncology (@JAMAOnc) February 9, 2023
Review | Management of adult patients with hematological malignancies in critical care
10 Feb, 2023 | 13:45h | UTCManagement of adult patients with haematological malignancies in critical care – Anaesthesia
Cohort Study | Risk of primary hematologic cancers following incident non-metastatic breast cancer
8 Feb, 2023 | 12:11h | UTC
Case-control study | Association of anthracycline with heart failure in patients treated for breast cancer or lymphoma, 1985-2010
6 Feb, 2023 | 13:20h | UTCInvited Commentary: Heart Failure in Patients With Cancer Treated With Anthracyclines—Revisiting the Foundation of Cardio-Oncology- JAMA Network Open
Commentary on Twitter
Anthracycline is linked to double the rate of heart failure in patients with cancer vs matched controls, 7.4% at 15 years. https://t.co/SxlJkJ7oLR
— JAMA Network Open (@JAMANetworkOpen) February 3, 2023
SR | Efficacy of CAR-T cell therapy vs. auto-HSCT in relapsed or refractory diffuse large B-cell lymphoma
6 Feb, 2023 | 13:06h | UTC
Preliminary study suggests chemotherapy delivery in the afternoon may improve outcomes in patients with DLBC lymphoma
1 Feb, 2023 | 13:27h | UTCCommentaries:
Chemotherapy schedule affects treatment outcomes in female DLBCL patients – News Medical
Cohort Study | Risk of malignant neoplasms of the gastrointestinal tract after blood or marrow transplant
30 Jan, 2023 | 00:23h | UTCMalignant Neoplasms of the Gastrointestinal Tract After Blood or Marrow Transplant – JAMA Oncology (link to abstract – $ for full-text)
Commentary: Risk of Subsequent Gastrointestinal Tract Malignancies After Blood or Marrow Transplantation – The ASCO Post
Commentary on Twitter
Exposure to cytarabine, etoposide and anthracyclines & chronic graft vs. host disease increase risk of colorectal, liver & esophageal cancer after BMT, providing evidence for appropriate evaluation & management in high-risk populations. https://t.co/UENFM1UWRw
— JAMA Oncology (@JAMAOnc) January 23, 2023
Post-trial follow-up | Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in early-stage unfavorable Hodgkin Lymphoma
27 Jan, 2023 | 11:58h | UTCCommentaries:
2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis
24 Jan, 2023 | 14:29h | UTCKey Points: 2023 ACC Expert Consensus on Cardiac Amyloidosis – American College of Cardiology
Commentary on Twitter
.@ACCinTouch's 🆕 Expert Consensus Decision Pathway provides practical and timely guidance on the diagnosis and management of cardiac #amyloidosis, with an emphasis on comprehensive multidisciplinary care.
Learn more: https://t.co/1SunbtuQpO#JACC #CardioOnc #CardioTwitter pic.twitter.com/DLvFUpajHC
— JACC Journals (@JACCJournals) January 23, 2023
ASCO Guideline | Management of fever and neutropenia in pediatric patients with cancer and hematopoietic cell transplantation recipients
24 Jan, 2023 | 14:28h | UTC
ESMO Guideline | Venous thromboembolism in cancer patients
15 Jan, 2023 | 20:21h | UTCVenous thromboembolism in cancer patients: ESMO Clinical Practice Guideline – Annals of Oncology
Related:
Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
An investigational T-cell therapy shows promise against six viral infections common after stem cell transplants
13 Jan, 2023 | 13:10h | UTC
Development and validation of a clinical prediction model for the prediction of 5-year survival in Hodgkin Lymphoma
13 Jan, 2023 | 13:12h | UTCCommentaries:
Commentary from the author on Twitter (thread – click for more)
👉With the dust from #ASH22 settled, we are happy to highlight the inaugural output from the #HoLISTIC consortium: The Advanced-stage cHL International Prognostication Index (A-HIPI) presented at @ASH_hematology w/ simult pub in @ASCO @JCO (https://t.co/em6HENzngk). A thread 1/16 pic.twitter.com/2kicNMBEIj
— Andrew M. Evens, DO, MBA, MSc (@DrAEvens) December 31, 2022
Phase 2 RCT | Upfront autologous HSCT vs. carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in multiple myeloma
12 Jan, 2023 | 12:56h | UTCInvited Commentary: Upfront autologous transplantation still improving outcomes in patients with multiple myeloma – The Lancet Haematology
Special Issue | American Society of Hematology Education Program (series of open-access review articles)
10 Jan, 2023 | 14:26h | UTCHomepage: American Society of Hematology Education Program – Hematology
RCT | Zanubrutinib vs. Ibrutinib in relapsed or refractory chronic lymphocytic leukemia.
16 Dec, 2022 | 13:33h | UTCZanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Zanubrutinib Found Superior to Ibrutinib for CLL and SLL – The ASCO Post
Single-arm P1 study | Talquetamab, a T-Cell–redirecting GPRC5D bispecific antibody for multiple myeloma.
12 Dec, 2022 | 12:38h | UTCTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Talquetamab, a bifunctional antibody, directs activated T cells to tumor. In this study, up to 70% of the patients with relapsed or refractory myeloma had a response to this agent. https://t.co/OJGHobKG0E pic.twitter.com/53soLSCepA
— NEJM (@NEJM) December 10, 2022